Unknown

Dataset Information

0

T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.


ABSTRACT: We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.

SUBMITTER: Noetzli J 

PROVIDER: S-EPMC5538043 | biostudies-other | 2017 Aug

REPOSITORIES: biostudies-other

Similar Datasets

2017-01-25 | GSE93980 | GEO
| S-EPMC1727061 | biostudies-other
| S-EPMC6241299 | biostudies-literature
2021-02-23 | GSE167271 | GEO
| S-EPMC6862380 | biostudies-literature
| S-EPMC8652067 | biostudies-literature
| S-EPMC8244595 | biostudies-literature
| S-EPMC4229192 | biostudies-literature
| S-EPMC7341149 | biostudies-literature
| S-EPMC1297250 | biostudies-literature